Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
The discussions predominantly focus on the potential of ezogabine as a new treatment for depression, with comments like 'very promising' and references to improvements in clinical scores. The tone ranges from supportive to cautiously optimistic, emphasizing both the relevance of the findings and the need for further research, which explains the high interest and engagement levels, as well as the moderate impact score based on its potential clinical significance.
AgreementModerate agreement
Most discussions acknowledge the study's findings, noting that ezogabine showed some clinical improvements despite limited neuroimaging changes, indicating general support for its potential as a treatment.
InterestHigh interest
The discussions demonstrate high interest by referencing novel mechanisms, clinical implications, and drug targets, reflecting curiosity among participants.
EngagementHigh engagement
Participants actively analyze the study’s details, mentioning specific outcomes like improvements in depression scores and neurochemical mechanisms, showing deep engagement.
ImpactModerate impact
Multiple posts highlight the significance of this research, framing it as a potential breakthrough or promising new avenue in depression treatment, although some temper expectations.
Abstract in brief
This study investigated whether ezogabine, a drug that opens KCNQ23 potassium channels, could improve brain activity related to reward and reduce depression and anhedonia symptoms in patients with depression.
The results showed that while ezogabine didn't significantly change brain activity during reward anticipation (the primary neuroimaging goal), it did lead to notable improvements in depression and anhedonia scores compared to placebo.
Overall, the findings suggest that targeting KCNQ23 channels might be a promising approach for treating depression and anhedonia, but more research is needed to confirm its effects on brain activity and clinical outcomes.
American Journal of Psychiatry Deputy Editor Daniel S. Pine, M.D., provides highlights of the April 2021 issue of the journal
Learn More: https://t.co/hTfgr9d8pt
May 11, 2021 · 2 likes · 11,606 followersView post →
P
P
@psychopharmacol · X
RCT: Although patients with MDD did not show a significant increase in ventral striatum response to reward anticipation with ezogabine, a KCNQ2/3 positive modulator, vs. placebo at 5 weeks, improvement was observed in the MADRS and SHAPS scores https://t.co/NPzfOn7m3m https://t.co/sEPLpWyZy5
Jun 9, 2021 · 2 likes · 1 share · 569 followersView post →
JA
Journals of The American Psychiatric Association
@APAPubJournals · X
The first randomized controlled trial investigating the effect of a KCNQ2/3 channel opener on brain & clinical measures linked to depression & anhedonia showed ezogabine treat. was associated w/ significant improvements in clinician & self-report measures.
https://t.co/2aPozGOHMG https://t.co/NYMJiZczER
Mar 4, 2021 · 1 like · 11,606 followersView post →
RB
Researching the Brain
@Brain_Database · X
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial | American Journal of Psychiatry https://t.co/Tn2Tq6Cn5F
#Depresión: Exploran Nuevos Tratamientos con diferentes Mecanismos de Acción: La #Ezogabina actúa sobre los Canales de Potasio cerebrales y parece mejorar la Anhedonia y otros Síntomas Depresivos. Vía @SEPsiqLegal https://t.co/ahaDmJslpY
Apr 20, 2021 · 1 like · 1 share · 699 followersView post →
AW
Alexis Whitton
@AlexisWhitton · X
New therapies for anhedonia also being trialled at @IcahnDAC by @JMurrough's team https://t.co/TIYXDBcKSn
American Journal of Psychiatry Deputy Editor Daniel S Pine MD highlights key studies from the May 2021 issue, including research on ezogabine's impact on reward circuitry and depressive symptoms in patients with…
This study investigated whether ezogabine, a drug that opens KCNQ23 potassium channels, could improve brain activity related to reward and reduce depression and anhedonia symptoms in patients with depression. The…
“This is an important example of how findings from basic animal models related to transdiagnostic domains such as reward processing and stress can identify promising novel drug targets in psychiatry.” 3/8
https://t.co/lNZQaoj0BJ
RCT: Although patients with MDD did not show a significant increase in ventral striatum response to reward anticipation with ezogabine, a KCNQ2/3 positive modulator, vs. placebo at 5 weeks, improvement was observed in the MADRS and SHAPS scores https://t.co/NPzfOn7m3m https://t.co/sEPLpWyZy5
Jun 9, 2021 · 2 likes · 1 share · 569 followersView post →
JA
Journals of The American Psychiatric Association
@APAPubJournals · X
American Journal of Psychiatry Deputy Editor Daniel S. Pine, M.D., provides highlights of the April 2021 issue of the journal
Learn More: https://t.co/hTfgr9d8pt
May 11, 2021 · 2 likes · 11,606 followersView post →
AB
Altamiro Bottino
@BottinoAltamiro · X
Researchers identify brain ion channel as new approach to treating depression
https://t.co/HucB17K39J
https://t.co/CRUQ2WyDCM https://t.co/LQ0Vq43wG2
#Depresión: Exploran Nuevos Tratamientos con diferentes Mecanismos de Acción: La #Ezogabina actúa sobre los Canales de Potasio cerebrales y parece mejorar la Anhedonia y otros Síntomas Depresivos. Vía @SEPsiqLegal https://t.co/ahaDmJslpY
Apr 20, 2021 · 1 like · 1 share · 699 followersView post →
AW
Alexis Whitton
@AlexisWhitton · X
New therapies for anhedonia also being trialled at @IcahnDAC by @JMurrough's team https://t.co/TIYXDBcKSn
RT @FIP_BPS: #Retigabine/#ezogabine, a drug that opens KCNQ2/3 #PotassiumChannels in the brain, shows promise as novel treatment for #depre…
Mar 23, 2021 · 2 shares · 6,173 followersView post →
PF
Pharmaceutical Science at FIP
@FIP_BPS · X
#Retigabine/#ezogabine, a drug that opens KCNQ2/3 #PotassiumChannels in the brain, shows promise as novel treatment for #depression, according to scientists @IcahnMountSinai, USA. https://t.co/BSSXG4GFwr Read the abstract here: https://t.co/xdxurqaea8
Mar 23, 2021 · 2 shares · 756 followersView post →
AW
Alexis Whitton
@AlexisWhitton · X
RT @UR_IDEA_Lab: New study out of @IcahnDAC provides evidence that Ezogabine, a novel antidepressant targeting neural ion channels, may all…
New study out of @IcahnDAC provides evidence that Ezogabine, a novel antidepressant targeting neural ion channels, may alleviate depression symptoms and anhedonia by mirroring "stress resilience" in the brain. https://t.co/LlBpXERIzF
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial [2021] via /r/Nootropics https://t.co/yEfb3f4SeI
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial [2021] via /r/Nootropics https://t.co/Kg8jXoqhSX
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial | American Journal of Psychiatry https://t.co/Tn2Tq6Cn5F
The first randomized controlled trial investigating the effect of a KCNQ2/3 channel opener on brain & clinical measures linked to depression & anhedonia showed ezogabine treat. was associated w/ significant improvements in clinician & self-report measures.
https://t.co/2aPozGOHMG https://t.co/NYMJiZczER
Mar 4, 2021 · 1 like · 11,606 followersView post →
A
andre
@AndrePGhetti · X
A possible new tool for the treatment of depression. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial | American Journal of Psychiatry https://t.co/55u2gv8ZWS
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial | American Journal of Psychiatry https://t.co/CwSsYlGdvW
https://doi.org/10.1176/appi.ajp.2020.20050653 breakthrough: Join the SciTechDaily newsletter. #brain #depression #mentalhealth #neuroscience · May be an ...
https://doi.org/10.1176/appi.ajp.2020.20050653 breakthrough: Join the SciTechDaily newsletter. #brain #depression #mentalhealth #neuroscience · Gali būti ...
P
JA
RB
AR
AW
RZ
AB
KY
PF
RL
RW
N
A
AE